Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T-cell/Histocyte-rich Large B-cell Lymphoma”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Early research (Phase 1)Study completedNCT03742258
What this trial is testing

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+4 more
Northwestern University 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04628494
What this trial is testing

Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Genmab 484
Large-scale testing (Phase 3)Study completedNCT02285062
What this trial is testing

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Celgene 570
Early research (Phase 1)Looking for participantsNCT05544019
What this trial is testing

Study of SGR-1505 in Mature B-Cell Neoplasms

Who this might be right for
Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more
Schrödinger, Inc. 98
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Testing effectiveness (Phase 2)Looking for participantsNCT07097363
What this trial is testing

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 18
Large-scale testing (Phase 3)Temporarily pausedNCT04799275
What this trial is testing

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Who this might be right for
Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma+18 more
National Cancer Institute (NCI) 422
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Early research (Phase 1)Looking for participantsNCT06544265
What this trial is testing

SynKIR-310 for Relapsed/Refractory B-NHL

Who this might be right for
B Cell LymphomaNHL, AdultMantle Cell Lymphoma+21 more
Verismo Therapeutics 18
Early research (Phase 1)Ended earlyNCT04933617
What this trial is testing

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Who this might be right for
Burkitt LymphomaHigh-grade B-cell LymphomaT-cell/Histocyte-rich Large B-cell Lymphoma+2 more
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Temporarily pausedNCT03704714
What this trial is testing

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more
Northwestern University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06834373
What this trial is testing

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Who this might be right for
Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more
Mayo Clinic 41
Testing effectiveness (Phase 2)Looking for participantsNCT06649812
What this trial is testing

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+12 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT05660967
What this trial is testing

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 111
Early research (Phase 1)Looking for participantsNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Testing effectiveness (Phase 2)Looking for participantsNCT05934448
What this trial is testing

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Who this might be right for
Primary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD 35
Testing effectiveness (Phase 2)Looking for participantsNCT05821088
What this trial is testing

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD
24
120
37